Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
SEMA, as a treatment for obesity, has shown nephroprotective effects, with a 22% reduction in the composite renal endpoint in the SELECT33 trial in patients without diabetes, supporting the role of SEMA in the management of the cardio-renal-metabolic syndrome
Results are reviewed by one of our GMC registered Doctors and sent to you via email along with our recommendations
Compare: Peptides offer targeted, often subtler shifts with fewer systemic side effects
However, this was a small study of 48 individuals and more research is needed to inform clinical decision making and treatment guidelines
US$ 29.65
US$ 27.17
US$ 23.59
US$ 26.08
